Johnson & Johnson $JNJ Stock Position Increased by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in Johnson & Johnson (NYSE:JNJ) by 12.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,158,903 shares of the company’s stock after purchasing an additional 127,100 shares during the quarter. Johnson & Johnson comprises 1.4% of VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings, making the stock its 9th largest position. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Johnson & Johnson were worth $214,884,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Evolution Wealth Management Inc. acquired a new stake in Johnson & Johnson during the 2nd quarter valued at approximately $27,000. Clayton Financial Group LLC acquired a new position in Johnson & Johnson during the third quarter valued at $28,000. Semmax Financial Advisors Inc. lifted its position in Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares during the period. GFG Capital LLC acquired a new stake in Johnson & Johnson during the 2nd quarter worth about $35,000. Finally, Signature Resources Capital Management LLC raised its stake in shares of Johnson & Johnson by 262.9% during the 3rd quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after buying an additional 184 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.1%

Shares of NYSE:JNJ opened at $207.26 on Friday. The business’s 50 day moving average price is $201.17 and its 200-day moving average price is $182.64. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $215.18. The firm has a market capitalization of $499.35 billion, a price-to-earnings ratio of 20.01, a price-to-earnings-growth ratio of 2.12 and a beta of 0.34. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion during the quarter. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.5%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s payout ratio is presently 50.19%.

Analyst Ratings Changes

JNJ has been the topic of a number of recent research reports. Loop Capital set a $190.00 target price on Johnson & Johnson in a research note on Wednesday, October 22nd. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Bank of America lifted their target price on shares of Johnson & Johnson from $204.00 to $220.00 and gave the company a “neutral” rating in a report on Monday, December 15th. Barclays boosted their target price on shares of Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research note on Tuesday. Finally, Stifel Nicolaus raised their price target on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a research report on Wednesday, October 15th. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $211.25.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.